Biontech Se ADR (BNTX)

$89.27 -0.04 (-0.04%)
Market Cap 21.42B
Revenue (ttm) 3.25B
Net Income (ttm) -1.29B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -39.59%
Debt to Equity Ratio 0.01
Volume 1,573,300
Avg Vol 1,239,808
Day's Range N/A - N/A
Shares Out 239.97M
Stochastic %K 62%
Beta 1.51
Analysts Strong Sell
Price Target $137.21

Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical tri...

Industry: Biotechnology
Sector: Healthcare
Phone: 49 6131 9084
Fax: 49 6131 9084
Address:
An der Goldgrube 12, Mainz, Germany
NasdaqKnight
NasdaqKnight Mar. 23 at 2:26 PM
LYME VACCINE: THE NEXT BIG INFECTIOUS DISEASE PLAY 👉Click to view @NasdaqKnight for timely updates amid the volatility. 476,000+ cases/year in the US. 300M+ at-risk in US/EU. No vaccine since 2002. That's about to change. $PFE — THE LEADER VLA15 (w/ Valneva) is the ONLY Phase 3 Lyme vaccine candidate Data readout: 1H 2026 (literally any day now) If approved: First-to-market in a $1B+ market $MRNA — THE CHALLENGER mRNA-1975/1982 in Phase 1/2 2026 catalysts: flu vaccine approval, flu/COVID combo, RSV data Cash position: $8.1B — ready to invest $BNTX — THE PLATFORM mRNA powerhouse. Oncology lead, but infectious disease pipeline in the wings The Setup: Lyme is the next major vaccine battleground. $PFE is months away from potentially owning it. $MRNA is right behind with mRNA tech. $BNTX is watching from the wings. Phase 3 data could drop any week. Don't sleep on this.
0 · Reply
BioTechHealthX
BioTechHealthX Mar. 22 at 3:56 PM
$BNTX BioNTech (NASDAQ:BNTX) is shifting from pandemic-driven revenue to a future powered by cancer therapies and next-generation vaccines. With a strong pipeline and cash reserves, this biotech stock is entering a new phase of growth. https://biotechhealthx.com/biotech-news/heres-why-you-should-consider-acquiring-biontech-bntx-shares/
0 · Reply
BioTechHealthX
BioTechHealthX Mar. 22 at 3:21 PM
$AXSM $BNTX $EXEL $REGN $VRTX Biotech stocks are heating up again in 2026. Discover 5 high-growth biotech companies with strong pipelines, FDA catalysts, and explosive upside potential investors are watching. https://biotechhealthx.com/biotech-news/top-5-biotech-stocks-that-could-explode-in-2026/
0 · Reply
NasdaqKnight
NasdaqKnight Mar. 22 at 2:24 PM
$BNTX $MRNA $NVAX $GILD: THE GREAT DIVERGENCE 👉Click to view @NasdaqKnight for timely updates amid the volatility. Weekly structures say bullish. Lower timeframes say otherwise. $MRNA Weekly: ADX 35.1 (trend conviction), +31.7% above EMA50 Daily/4h: bearish MACD, upside prob only 18% / 20% RSI weekly at 67.4 — mature uptrend $BNTX Weekly bearish (-26.0 mom, CMF -0.197) but ADX 17.6 (weak conviction) Daily CMF +0.358 vs 4h +0.060 — positive divergence BUT ML prob: 17% (daily) / 11% (4h) — money flow ≠ follow-through $NVAX Weekly +16.9% above EMA50, ADX 33.8 BUT weekly CMF turned negative (-0.147) — distribution Lower timeframe prob: 25% / 21% $GILD — most alarming 4h upside probability: 3% 4h RSI 26.5 oversold, but model says bounces unlikely to sustain Conclusion: Bullish weekly + collapsing lower timeframe probabilities = topping process, not consolidation.
1 · Reply
AStrokeOfLuck
AStrokeOfLuck Mar. 21 at 7:12 PM
$PFE $MRNA $BNTX $SPY $NVAX
1 · Reply
wheresdannynow
wheresdannynow Mar. 20 at 7:22 PM
Animal health entering the mRNA phase. AI optimized vaccines + next gen delivery targeting dogs and cats is a real growth lane. $MRNA $BNTX $ZTS proving how valuable vaccine platforms can be. $BIOV advancing DPX + mRNA into companion animals = optionality.
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Mar. 20 at 6:30 PM
$NNVC : From Manufacturing to Clinical Execution NanoViricides has completed manufacturing of its NV-387 oral drug, a key step ahead of Phase 2 trials. With production in place, the company is preparing to enter clinical-stage testing, initially focused on Mpox. NV-387 is part of a broad-spectrum antiviral platform targeting multiple viruses, including coronaviruses, influenza, and RSV. Key implications: 🟰Removes a major manufacturing hurdle 🟰Enables progression into Phase 2 trials 🟰Supports a multi-indication platform strategy What to watch: 🟰Phase 2 initiation and data 🟰Clinical efficacy signals 🟰 Expansion into additional viral targets NNVC remains early-stage, but this milestone marks a clear step toward unlocking the platform’s broader potential. Communicated Disclaimer: https://tinyurl.com/TherealshortsqueezyNNVC Peers: $PFE $MRNA $BNTX $GILD
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Mar. 20 at 3:21 PM
$NNVC: The Broad-Spectrum Antiviral Play No One’s Watching NanoViricides is developing broad spectrum antivirals that bind to and neutralize viruses directly. Their lead candidate (NV-387) targets COVID, flu, RSV, and Mpox, aiming for a platform, not a single drug. Recent milestones 🔸Completed Phase 1 safety trials 🔸Advanced manufacturing for Phase 2-ready drug 🔸Preparing for Phase 2 (Mpox focus) Catalysts 🔸Phase 2 launch + data 🔸Expansion into additional viral targets 🔸Regulatory updates / partnerships The antiviral market is already ~$60–70B, with long-term growth toward ~$90B+ NNVC is a microcap trying to capture that with a multi-virus approach Communicated Disclaimer: https://tinyurl.com/TherealshortsqueezyNNVC Peers: $PFE $MRNA $BNTX $GILD
0 · Reply
taxplanr
taxplanr Mar. 20 at 2:50 PM
$BNTX $MRNA $PFE AAP under fire everywhere https://thepostmillennial.com/myocarditis-found-only-in-covid-vaxxed-kids-study#google_vignette
0 · Reply
taxplanr
taxplanr Mar. 20 at 1:02 PM
Devastating childhood study shows only COVID vaccinated children suffered heart damage $BNTX $MRNA $PFE https://pmc.ncbi.nlm.nih.gov/articles/PMC12643559/
0 · Reply
Latest News on BNTX
BioNTech SE (BNTX) Q4 2025 Earnings Call Transcript

Mar 10, 2026, 5:40 PM EDT - 12 days ago

BioNTech SE (BNTX) Q4 2025 Earnings Call Transcript

BioNTech Stock Tanks As Outlook, Founder Exit Rattle Bulls

Mar 10, 2026, 3:39 PM EDT - 12 days ago

BioNTech Stock Tanks As Outlook, Founder Exit Rattle Bulls

BioNTech SE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Mar 10, 2026, 2:48 PM EDT - 12 days ago

BioNTech SE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

One simple reason why BioNTech stock is a raging buy on today's crash

Mar 10, 2026, 1:29 PM EDT - 12 days ago

One simple reason why BioNTech stock is a raging buy on today's crash

BioNTech Stock Tumbles As Co-Founders Pivot To New MRNA Venture

Mar 10, 2026, 8:40 AM EDT - 13 days ago

BioNTech Stock Tumbles As Co-Founders Pivot To New MRNA Venture

Scientists behind COVID-19 vaccine will depart BioNTech

Mar 10, 2026, 7:40 AM EDT - 13 days ago

Scientists behind COVID-19 vaccine will depart BioNTech

BioNTech Plunges as Drugmaker Swings to a Loss. More Than Earnings Are Weighing on the Stock.

Mar 10, 2026, 7:18 AM EDT - 13 days ago

BioNTech Plunges as Drugmaker Swings to a Loss. More Than Earnings Are Weighing on the Stock.

BioNTech Cofounders to Leave to Form New Company

Mar 10, 2026, 6:50 AM EDT - 13 days ago

BioNTech Cofounders to Leave to Form New Company

BioNTech's founding couple Sahin, Tuereci to leave to set up new venture

Mar 10, 2026, 6:49 AM EDT - 13 days ago

BioNTech's founding couple Sahin, Tuereci to leave to set up new venture

BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

Mar 10, 2026, 6:45 AM EDT - 13 days ago

BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030

Mar 10, 2026, 6:33 AM EDT - 13 days ago

BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030

BioNTech: The Market Is Pricing Low Oncology Success

Feb 25, 2026, 9:46 AM EST - 26 days ago

BioNTech: The Market Is Pricing Low Oncology Success

BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026

Feb 24, 2026, 6:45 AM EST - 27 days ago

BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026

BioNTech sues Moderna for patent infringement over COVID-19 shots

Feb 19, 2026, 1:25 PM EST - 4 weeks ago

BioNTech sues Moderna for patent infringement over COVID-19 shots

MRNA

BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer

Jan 28, 2026, 8:00 AM EST - 7 weeks ago

BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer

BioNTech SE (BNTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 10:45 PM EST - 2 months ago

BioNTech SE (BNTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 6:45 AM EST - 2 months ago

BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference

University of Pennsylvania, BioNTech, and OUP Launch $50 Million Life Sciences Fund

Jan 9, 2026, 10:00 AM EST - 2 months ago

University of Pennsylvania, BioNTech, and OUP Launch $50 Million Life Sciences Fund

BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field

Dec 18, 2025, 4:45 AM EST - 3 months ago

BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field

BioNTech: Maintaining "Strong Buy" After Part 1 Success Of Next-Gen Anti-CTLA-4 Gotistobart

Dec 9, 2025, 5:54 PM EST - 3 months ago

BioNTech: Maintaining "Strong Buy" After Part 1 Success Of Next-Gen Anti-CTLA-4 Gotistobart

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer

Dec 9, 2025, 7:00 AM EST - 3 months ago

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer

BMY

BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer

Dec 6, 2025, 3:30 PM EST - 3 months ago

BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer

BioNTech Achieves Minimum Condition in CureVac Exchange Offer

Dec 3, 2025, 9:01 AM EST - 3 months ago

BioNTech Achieves Minimum Condition in CureVac Exchange Offer

CVAC

FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks

Dec 1, 2025, 3:50 PM EST - 3 months ago

FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks

MRNA NVAX PFE

Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men

Dec 1, 2025, 12:35 PM EST - 3 months ago

Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men

MRNA NVAX PFE

BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration

Nov 26, 2025, 7:30 AM EST - 4 months ago

BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration

BioNTech SE (BNTX) Discusses Oncology Innovation Strategy, Combination Therapies and Personalized Cancer Immunotherapies Transcript

Nov 17, 2025, 6:17 PM EST - 4 months ago

BioNTech SE (BNTX) Discusses Oncology Innovation Strategy, Combination Therapies and Personalized Cancer Immunotherapies Transcript

Pfizer sheds BioNTech stake years after blockbuster COVID vaccine tie-up

Nov 13, 2025, 5:20 PM EST - 4 months ago

Pfizer sheds BioNTech stake years after blockbuster COVID vaccine tie-up

PFE

Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run

Nov 13, 2025, 11:10 AM EST - 4 months ago

Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run

PFE

BioNTech says collaboration with Pfizer remains unchanged

Nov 13, 2025, 8:17 AM EST - 4 months ago

BioNTech says collaboration with Pfizer remains unchanged

PFE

BioNTech Q3 Earnings: Plenty Of Cash And Pipeline Potential, But Still A Hold

Nov 3, 2025, 1:44 PM EST - 4 months ago

BioNTech Q3 Earnings: Plenty Of Cash And Pipeline Potential, But Still A Hold

BioNTech SE (BNTX) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 12:46 PM EST - 4 months ago

BioNTech SE (BNTX) Q3 2025 Earnings Call Transcript

BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership

Nov 3, 2025, 10:29 AM EST - 4 months ago

BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership

BMY

BioNTech lifts 2025 revenue guidance on BMS partnership payment

Nov 3, 2025, 6:47 AM EST - 5 months ago

BioNTech lifts 2025 revenue guidance on BMS partnership payment

BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update

Nov 3, 2025, 6:45 AM EST - 5 months ago

BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update

BioNTech to Host Innovation Series R&D Day on November 11, 2025

Oct 28, 2025, 7:45 AM EDT - 5 months ago

BioNTech to Host Innovation Series R&D Day on November 11, 2025

BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025

Oct 27, 2025, 7:45 AM EDT - 5 months ago

BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025

BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.

Oct 22, 2025, 6:45 AM EDT - 5 months ago

BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.

Moderna Vs BioNTech: Who's Winning The Post-COVID Race

Oct 18, 2025, 9:30 AM EDT - 5 months ago

Moderna Vs BioNTech: Who's Winning The Post-COVID Race

MRNA

BioNTech SE, InstaDeep Ltd - Special Call

Oct 1, 2025, 6:52 PM EDT - 6 months ago

BioNTech SE, InstaDeep Ltd - Special Call

BioNTech to Host Second AI Day as an Edition of Its Innovation Series on October 1, 2025

Sep 23, 2025, 6:45 AM EDT - 6 months ago

BioNTech to Host Second AI Day as an Edition of Its Innovation Series on October 1, 2025

Mizuho's Jared Holz: There's not much value left in vaccine stocks

Sep 19, 2025, 11:40 AM EDT - 6 months ago

Mizuho's Jared Holz: There's not much value left in vaccine stocks

MRNA NVAX PFE

COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says

Sep 12, 2025, 1:37 PM EDT - 6 months ago

COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says

JNJ KVUE MRNA PFE

BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy

Sep 8, 2025, 2:01 PM EDT - 6 months ago

BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy

BMY

BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial

Sep 8, 2025, 11:05 AM EDT - 6 months ago

BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial

BMY

First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity

Sep 8, 2025, 11:00 AM EDT - 6 months ago

First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity

Pfizer, partner BioNTech say updated COVID shot shows better immune response

Sep 8, 2025, 7:02 AM EDT - 7 months ago

Pfizer, partner BioNTech say updated COVID shot shows better immune response

PFE

Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula

Sep 8, 2025, 6:45 AM EDT - 7 months ago

Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula

PFE

BioNTech, Duality score initial trial win with breast cancer precision drug

Sep 5, 2025, 5:13 AM EDT - 7 months ago

BioNTech, Duality score initial trial win with breast cancer precision drug

mRNA Biotechs - Long-Term Value Risks Abound

Aug 28, 2025, 6:20 AM EDT - 7 months ago

mRNA Biotechs - Long-Term Value Risks Abound

ALNY DHR GRAL ILMN IONS MRNA RGEN

NasdaqKnight
NasdaqKnight Mar. 23 at 2:26 PM
LYME VACCINE: THE NEXT BIG INFECTIOUS DISEASE PLAY 👉Click to view @NasdaqKnight for timely updates amid the volatility. 476,000+ cases/year in the US. 300M+ at-risk in US/EU. No vaccine since 2002. That's about to change. $PFE — THE LEADER VLA15 (w/ Valneva) is the ONLY Phase 3 Lyme vaccine candidate Data readout: 1H 2026 (literally any day now) If approved: First-to-market in a $1B+ market $MRNA — THE CHALLENGER mRNA-1975/1982 in Phase 1/2 2026 catalysts: flu vaccine approval, flu/COVID combo, RSV data Cash position: $8.1B — ready to invest $BNTX — THE PLATFORM mRNA powerhouse. Oncology lead, but infectious disease pipeline in the wings The Setup: Lyme is the next major vaccine battleground. $PFE is months away from potentially owning it. $MRNA is right behind with mRNA tech. $BNTX is watching from the wings. Phase 3 data could drop any week. Don't sleep on this.
0 · Reply
BioTechHealthX
BioTechHealthX Mar. 22 at 3:56 PM
$BNTX BioNTech (NASDAQ:BNTX) is shifting from pandemic-driven revenue to a future powered by cancer therapies and next-generation vaccines. With a strong pipeline and cash reserves, this biotech stock is entering a new phase of growth. https://biotechhealthx.com/biotech-news/heres-why-you-should-consider-acquiring-biontech-bntx-shares/
0 · Reply
BioTechHealthX
BioTechHealthX Mar. 22 at 3:21 PM
$AXSM $BNTX $EXEL $REGN $VRTX Biotech stocks are heating up again in 2026. Discover 5 high-growth biotech companies with strong pipelines, FDA catalysts, and explosive upside potential investors are watching. https://biotechhealthx.com/biotech-news/top-5-biotech-stocks-that-could-explode-in-2026/
0 · Reply
NasdaqKnight
NasdaqKnight Mar. 22 at 2:24 PM
$BNTX $MRNA $NVAX $GILD: THE GREAT DIVERGENCE 👉Click to view @NasdaqKnight for timely updates amid the volatility. Weekly structures say bullish. Lower timeframes say otherwise. $MRNA Weekly: ADX 35.1 (trend conviction), +31.7% above EMA50 Daily/4h: bearish MACD, upside prob only 18% / 20% RSI weekly at 67.4 — mature uptrend $BNTX Weekly bearish (-26.0 mom, CMF -0.197) but ADX 17.6 (weak conviction) Daily CMF +0.358 vs 4h +0.060 — positive divergence BUT ML prob: 17% (daily) / 11% (4h) — money flow ≠ follow-through $NVAX Weekly +16.9% above EMA50, ADX 33.8 BUT weekly CMF turned negative (-0.147) — distribution Lower timeframe prob: 25% / 21% $GILD — most alarming 4h upside probability: 3% 4h RSI 26.5 oversold, but model says bounces unlikely to sustain Conclusion: Bullish weekly + collapsing lower timeframe probabilities = topping process, not consolidation.
1 · Reply
AStrokeOfLuck
AStrokeOfLuck Mar. 21 at 7:12 PM
$PFE $MRNA $BNTX $SPY $NVAX
1 · Reply
wheresdannynow
wheresdannynow Mar. 20 at 7:22 PM
Animal health entering the mRNA phase. AI optimized vaccines + next gen delivery targeting dogs and cats is a real growth lane. $MRNA $BNTX $ZTS proving how valuable vaccine platforms can be. $BIOV advancing DPX + mRNA into companion animals = optionality.
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Mar. 20 at 6:30 PM
$NNVC : From Manufacturing to Clinical Execution NanoViricides has completed manufacturing of its NV-387 oral drug, a key step ahead of Phase 2 trials. With production in place, the company is preparing to enter clinical-stage testing, initially focused on Mpox. NV-387 is part of a broad-spectrum antiviral platform targeting multiple viruses, including coronaviruses, influenza, and RSV. Key implications: 🟰Removes a major manufacturing hurdle 🟰Enables progression into Phase 2 trials 🟰Supports a multi-indication platform strategy What to watch: 🟰Phase 2 initiation and data 🟰Clinical efficacy signals 🟰 Expansion into additional viral targets NNVC remains early-stage, but this milestone marks a clear step toward unlocking the platform’s broader potential. Communicated Disclaimer: https://tinyurl.com/TherealshortsqueezyNNVC Peers: $PFE $MRNA $BNTX $GILD
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Mar. 20 at 3:21 PM
$NNVC: The Broad-Spectrum Antiviral Play No One’s Watching NanoViricides is developing broad spectrum antivirals that bind to and neutralize viruses directly. Their lead candidate (NV-387) targets COVID, flu, RSV, and Mpox, aiming for a platform, not a single drug. Recent milestones 🔸Completed Phase 1 safety trials 🔸Advanced manufacturing for Phase 2-ready drug 🔸Preparing for Phase 2 (Mpox focus) Catalysts 🔸Phase 2 launch + data 🔸Expansion into additional viral targets 🔸Regulatory updates / partnerships The antiviral market is already ~$60–70B, with long-term growth toward ~$90B+ NNVC is a microcap trying to capture that with a multi-virus approach Communicated Disclaimer: https://tinyurl.com/TherealshortsqueezyNNVC Peers: $PFE $MRNA $BNTX $GILD
0 · Reply
taxplanr
taxplanr Mar. 20 at 2:50 PM
$BNTX $MRNA $PFE AAP under fire everywhere https://thepostmillennial.com/myocarditis-found-only-in-covid-vaxxed-kids-study#google_vignette
0 · Reply
taxplanr
taxplanr Mar. 20 at 1:02 PM
Devastating childhood study shows only COVID vaccinated children suffered heart damage $BNTX $MRNA $PFE https://pmc.ncbi.nlm.nih.gov/articles/PMC12643559/
0 · Reply
htw7448
htw7448 Mar. 19 at 4:13 PM
$BNTX insane how low a company with ground breaking P3 candidates can go. First major readouts around the corner. Boat loaded
0 · Reply
Ventureville
Ventureville Mar. 19 at 2:10 PM
mRNA is expanding beyond humans. Veterinary vaccines for rabies, lepto, FIP signal how fast the platform is scaling into animal health, a multi billion runway. Names like $MRNA $BNTX $ARCT pushing the tech forward. $BIOV.CSE / $BVAXF riding the broader immunotherapy and platform wave as mRNA and next gen delivery gain traction. Science scales. Markets follow.
1 · Reply
taxplanr
taxplanr Mar. 19 at 2:08 PM
Ivermectin Fenbendazole and Mebendazole kicking Melanoma's butt $BNTX $MRNA $PFE https://makisw.substack.com/p/ivermectin-fenbendazole-and-mebendazole-f5d?utm_source=post-email-title&publication_id=1385328&post_id=191449364&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply
taxplanr
taxplanr Mar. 18 at 10:20 PM
Argentina withdraws from WHO $BNTX $MRNA $PFE https://www.thegatewaypundit.com/2026/03/health-sovereignty-javier-mileis-argentina-follows-us-officially/
0 · Reply
Pillemann1
Pillemann1 Mar. 18 at 7:47 PM
$BNTX 5% down, 5% up …..booooaaaringg! So much patience needed here.
0 · Reply
Ventureville
Ventureville Mar. 18 at 5:22 PM
Animal health + immuno oncology are heating up. Zero approved mRNA vaccines for companion animals despite multi-billion markets. Human side, HER2 and checkpoint combos expanding as $MRK $BMY $BNTX push next gen platforms. Patent cliffs are coming. Partnering demand rises. $BIOV.CSE / $BVAXF around C$7M market cap with 120+ patents from a platform once valued ~$330M as IMV. Sector tailwinds + platform IP = asymmetric setup.
0 · Reply
Find_the_Cure
Find_the_Cure Mar. 18 at 4:14 PM
$MRNA $PFE $BNTX when will these mRNA vaccine companies be eligible for class action LAWSUITS by losing their Covid vaccine protection status?!?
0 · Reply
htw7448
htw7448 Mar. 18 at 3:35 PM
$BNTX again nice buying opportunity
0 · Reply
Game_Day
Game_Day Mar. 18 at 3:05 PM
SWMR 👊 half way through goals $AIRS $BNTX $NOW $SWMR
0 · Reply
taxplanr
taxplanr Mar. 18 at 2:27 PM
since 1906 $BNTX $MRNA $BMY $MRK https://www.instagram.com/reel/DVgK_mmk0VV/?igsh=MXcwa3ZkMm54OTR5Zg==
0 · Reply
taxplanr
taxplanr Mar. 18 at 1:59 PM
Ivermectin and Fenbendazole working again on Prostte Cancer $BNTX $MRNA $BMY $MRK https://makisw.substack.com/p/ivermectin-and-fenbendazole-testimonial-a3a?utm_source=post-email-title&publication_id=1385328&post_id=191339180&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply
taxplanr
taxplanr Mar. 18 at 1:56 PM
So how long has the conspiracy to cover up cures for cancer has been going on? $BNTX $MRNA $BMY $MRK https://makisw.substack.com/p/cancer-research-lactoferrin-2025?utm_source=post-email-title&publication_id=1385328&post_id=191337555&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply